Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Pete Patterson started Vitalis in Kelowna, BC and Valcon gets their extraction equipment from Vitalis.
https://www.kelownadailycourier.ca/business_news/article_f5ce6d80-5e05-11e8-aa5b-2f674361596d.html
Pete Patterson CEO of Valcon interview
Ted Ohashi May 30
https://4495825a-d729-4d8f-ade8-e78f828e1c8d.usrfiles.com/ugd/449582_3230d4f73e0948dc8f8ec92572714bad.pdf
Here are some thoughts on Lexaria Bioscience (NASDAQ: LEXX) (NASDAQ: LEXXW). Blood pressure is equal to cardiac output times systemic vascular resistance. In other words, the pressure the
blood is exerting on the walls of your artery is equivalent to cardiac output (the amount of blood being
pushed out of your left ventricle over time) multiplied by the systemic vascular resistance or the resistance your arterials are putting on the blood behind it. This is important because your arterials have
smooth muscle wrapped around them and the smooth muscle can either constrict or dilate. If the
smooth muscle constricts, it makes is harder for the blood to pass through, or, it increases blood pressure. On the other hand, if it dilates, there is more room for the blood to pass through and the blood
pressure declines. This means that all the antihypertensive drugs we use to treat blood pressure either
reduces the cardiac output or it reduces systemic vascular resistance.
Lexaria’s human clinical study HYPER-H21-2 confirmed DehydraTECH™-processed cannabidiol
(CBD) reduced arterial stiffness. This finding potentially broadened its application to the treatment of
cardiovascular and other disease states beyond hypertension. DehydraTECH™ has already shown
tremendous promise in lowering blood pressure but if it can actually contribute to the treatment of the
causes of high blood pressure or other diseases, that would be a significantly more important, valuableadded. President John Docherty called it a “major discovery.” He went on to say, "We know that increased arterial stiffness is correlated with many serious and life-threatening diseases affecting people
worldwide, and we are optimistic that our latest findings could have future widespread implications for
promotion of improved human health and wellness."
“The efficacy of blood pressure treatment and differences in efficacy between different types of antihypertensive agents is strongly correlated with measuring arterial stiffness…DehydraTECH-CBD from
study HYPER-H21-2 appear to have been at least partially due to improvements in arterial stiffness.”
“To have decreased arterial stiffness to the degree demonstrated in our present study after only a
single day of dosing with DehydraTECH-CBD is quite remarkable and will be more thoroughly investigated in Lexaria's upcoming 6-week hypertension study HYPER-H21-4, where multiple doses over this
period are expected to demonstrate additional benefits against hypertension and arterial stiffness.”
9
An article by Rekha Mankad, M.D. of the Mayo Clinic confirms this information in a slightly different
way. Blood pressure readings are in two numbers. The top number is the systolic pressure or the
highest pressure the heart exerts while beating and the second number is the diastolic pressure or the
pressure in the arteries between heart beats. The systolic pressure (say 120) minus the diastolic pressure (say 80) is the pulse pressure (120-80=) 40. Generally, a pulse pressure over 40 is considered
unhealthy. A pulse pressure of over 60 is considered a risk factor for cardiovascular disease. Stiffness
of the aorta is the leading cause of higher blood pressure and is thought to contribute to stiffening of
the arteries. Treating high blood pressure usually means reducing pulse pressure.
What does this tell us? It means the ability of DehydraTECH-CBD as first detected in HYPER-H21-2
to lower blood pressure was due, in part, to improvements in arterial stiffness. This will be one important
finding to look for when we see the results from hypertension study HYPER-H21-4 that is currently
underway. If there are additional signs of reductions in arterial stiffness the market response could be
explosive. We could see preliminary results from HYPER-H21-4 as early as late July and certainly
almost complete results by early fall.
The hypertension market is valued at $28 billion per year and is expected to continue growing as one
of the world's top health problems. Geographically, some of the highest rates of growth are expected
in more recently industrialized nations such as China and India. Over 1.1 billion people worldwide suffer from hypertension - elevated blood pressure. Hypertension is a major risk factor for cardiovascular
and cerebrovascular disease, and accounts for approximately 45% of cardiovascular disease mortality
and morbidity worldwide. Drugs focused on blood pressure and related conditions such as Lipitor and
Plavix are some of the highest selling drugs in the world. There are several hypertension drugs that
each generate $1 billion per year or more in revenue.
Finally, in my latest interview with CEO Chris Bunka, we discussed the growing potential for a significant commercial agreement. The company has been in discussions with more high profile businesses
than ever before in LEXX’s history. If one of these results in a commercial contract, it could also help
get the stock price moving up towards a valuation that some multiple of the current price that I believe
is more realistic.
Conclusion: Although the cannabis stocks are trading in a volatile and uncertain fashion, the type of
news that LEXX is capable of generating over the next few months can move the stock higher against
the general trend.
Along with many
stocks, LEXX is
trading at an excessively low
level. The current
market cap
10
according to Yahoo Finance is $12.3 million. For a company with multiple prospects that offer the potential for a breakthrough market re-evaluation, I consider this an excessive undervaluation and an
opportunity waiting to happen
LEXXW hit a high of $1.63 today, now at $1.00.
Ted Ohashi-Bunka Interview Pg. 6
https://4495825a-d729-4d8f-ade8-e78f828e1c8d.usrfiles.com/ugd/449582_8974e903d744400a8f0bd05b703a21c3.pdf
I guess they hang onto them in the hope that someday they'll increase in value. If they sold them now, even if they could find a buyer, it would mean that they sold the rights to Hill Street for a pittance. Shares in Hill Street are near worthless. .025/sh.
No wonder we're on a roll, we just got 4.18 million shares of Hill Street worth a whole CDN$125,400. Wow! Whoopee!
Mr. Craig Binkley reports
HILL STREET ISSUES FINAL TRANCHE OF PAYMENT SHARES TO LEXARIA FOR DEHYDRATECH(TM) PATENT RIGHTS ACQUISITION
Hill Street Beverage Company Inc. has issued 4,188,948 common shares to Lexaria CanPharm ULC, a cannabis-related division of Lexaria Bioscience Corp., as the third and final tranche of shares to be issued in satisfaction of a deferred payment obligation for the previously announced acquisition by Hill Street of the exclusive global rights to use Lexaria's groundbreaking DehyraTech patent portfolio to produce non-pharmaceutical products containing 0.3 per cent or greater THC (tetrahydrocannabinol) and other psychoactive cannabinoids.
"The acquisition of the rights to DehyraTech has transformed our business financially, operationally and geographically, as evidenced by the company's strong growth and financial performance detailed in the update we shared last week," stated Hill Street chief executive officer Craig Binkley. "The key metrics of the business have improved substantially since this acquisition was completed 16 months ago, and we are expanding geographically on the early success of DehyraTech licensing with multiple licensees."
In accordance with the terms of the acquisition, the consideration shares were issued at a deemed price of 8.5 cents per share, being the closing price of Hill Street's common shares on the TSX Venture Exchange on Nov. 18, 2020, the date that the acquisition agreement was executed.
The consideration shares will be subject to a statutory hold period expiring on the date that is four months and one day from the issuance date.
About Hill Street Beverage Company Inc.
Hill Street Beverage Company is a progressive non-alcoholic beverage and cannabis solutions company. It is pioneering the space where craft consumer products meet bioscience by combining its deep CPG (consumer packaged good) expertise and its rights to use Lexaria Bioscience's groundbreaking DehyraTech patent portfolio for product development, licensing and B2B (business-to-business) sales of cannabis ingredients.
Hill Street Beverages brands include Vin(Zero) alcohol-free wines, and Hill Avenue Cannabis Brands include (V)ia Regal Pink and White Grape Sparklers.
We seek Safe Harbor.
Lexaria Commences Multi-Week Human Clinical Hypertension Study
http://crweworld.com/article/news-provided-by-accesswire/2356110/lexaria-commences-multi-week-human-clinical-hypertension-study
I bet you're right, but I've been wrong before! LOL
"...test articles are currently being manufactured." You have to wonder if theses are the same compounds that Altria is paying Lexaria to manufacture.
I would hazard a guess and say that Lexaria has given up on fully orally ingestable nicotine products and is now concentrating on proving the viability of a product that can be absorbed through the buccal tissues. It's unclear whether the compounds that are being readied for Altria are of this type.
Interim Financials are out.
It appears so, at least partially. Looking forward to being completely wrong. LOL
Ted Ohashi-Page 9
https://4495825a-d729-4d8f-ade8-e78f828e1c8d.usrfiles.com/ugd/449582_5aceab90777d4af28a0f0f7e5fdf2d0f.pdf
Question of the Week
“I received a lot of positive feedback following my interview with Chris Bunka, Chief Executive Officer
of Lexaria Bioscience (NASDAQ: LEXX) (NASDAQ: LEXXW) last week however, the one issue several people questioned was the delay in receiving results from the Hypertension #3 study.
The questions I received about Hypertension #3 covered a wide range of issues including:
1. It is hard to believe the results have been in for over three months and haven’t been analysed.
2. If there was good news, it would have been reported right away.
3. Bad news is always late.
4. How can you start Hypertension #4 when #3 hasn’t been completed?
9
Let me start out by saying I have known and followed Chris Bunka for six years now and he has never
once lied to me. I’m not saying all of his expectations have come to fruition exactly as anticipated but
in business, not everything works out as you expect. This is a totally normal characteristic of operating
a company. I believe Bunka is a person of high integrity and character.
I asked Lexaria Bioscience (CSE: LXX) (NASDAQ: LEXX) (NASDAQ: LEXXW) Chief Executive Officer Chris Bunka about your concerns. Here are his responses.
• Without equivocation, we simply do not have the results yet. No fudging.
No hedging. We do not have the results. We engaged two additional PhDs ourselves and there are another six that were added through our regulatory consulting firm. We are struggling to keep up with the all the compliance and data assessment.
• To give you some idea of what is involved in one of these larger studies,
our upcoming human nicotine study will produce approximately 1,200 vials of blood. Each of
those vials will be analysed for around a dozen different variables. Each sample also has to be
properly processed, labelled and stored. That's around 14,000 pieces of data that need to be
reviewed. It simply takes a long time to complete.
• We have had a very active testing program going on in 2021 to 2023 but we do have limited
resources. As a result, we have to prioritize our activities and are staying focussed on what we
believe are the most important priorities for achieving commercialization. We believe getting
Hyper H21 4 launched on time is far more important than data analysis from Hyper H21 3. The
Hypertension #3 analysis is important but not as important from a commercial point of view.
• Please impress upon your readers that we have a lot of work to do and we are going as fast as
week can. Anyone who thinks there is something else afoot is mistaken.
Conclusion: as closely as investors might follow a company, it is never the same as being there day
by day. I believe Bunka has provided a clear and concise answer to the question. As I have said many
times in the past
few quarters, I believe LEXX has a
major opportunity
in hypertension.
That is why management has decided to carry
their work in hypertension further along into the FDA approval process. If they are successful, the
results for shareholders will be remarkable, in my opinion. I have consistently had Lexaria Bioscience
(NASDAQ: LEXX) (NASDAQ: LEXXW) as one of my favourites. Perhaps this gives readers some
further input into why I rate them so highly.
OK, well let me know when I'm wrong. Thanks
Correction, Bunka has never told us whether Altria has said that they are in or out. It's been over 3 years since Altria first agreed to fund research into DehydraTECH and nicotine and they have not put one cent of additional money into funding any further research as allowed in the agreement. So, are they in or out? I think the answer is obvious!
https://ir.lexariabioscience.com/news-events/press-releases/detail/52/altria-group-invests-up-to-12m-in-lexaria-biosciences
I don't know how many tuned in. I couldn't be bothered after there was no news in the morning, I got those highlights from someone who did.
I just don't believe him any more, this story about being too busy to do the analysis of HYPER-H21-3 results is pure BS, and now I think he's doing a bait and switch, heh, don't worry about hypertension, look at the nicotine card I just pulled out of the hat again, and don't worry I might have some important news down the road.
Altria has not put any more money into nicotine research re: DehydraTECH, as per their agreement with Lexaria, since their original investigation concluded, so what is Bunka talking about?
'As a result, Altria now has 90 days, or until 11:59 pm on October 8, 2020 to exercise its First Warrant Tranche by way of a further staged payment to Lexaria Nicotine as per the agreements among the parties. This payment would enable Altria to retain its current exclusivity in the US market for Lexaria's DehydraTECHTM for purposes of oral nicotine delivery.'
A few highlights…
1. Roughly $8.5 M in cash at this time. No plans of any financing and fully funded until mid 2023.
2. Deals with both Altria and BAT are ongoing. Claims there is far more happening with Altria as of now than BAT.
3. Promises at least 6 major news items in the next 6 months; all having the potential to move the stock in a significant way.
Greetings,
Please join us again welcoming returning company Lexaria Bioscience, Corp. (NASDAQ: LEXX). The company will be providing an update on Thursday, March 24th at 4:30 pm EST. It's been 8 months since they last presented to our investment community. Please take this opportunity to re-connect with the company.
Please join us
For this exclusive corporate presentation, followed by a Q & A session moderated by Bear Creek Capital, featuring questions taken from the audience.
**Must register to receive a webinar link
This Zoom Webinar is an invitation only event and is reserved for accredited investors. The presentation will include an overview of the company's story with recent highlights, followed by a question and answer forum.
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp.'s patented drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by up to 5-10x, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 24 patents granted and over 50 patents pending worldwide.
Share Price: $3.04
Market Cap: 18.389 M
Avg. Volume: 78,275
Source: Yahoo Finance
LIVE WEBINAR ON March 24th at 4:30 PM EST
Get up, close and personal with Lexaria Bioscience's Chairman and CEO, Christopher Bunka. Learn about their technologies and the outlook of where the company is going.
Please register to Attend Event
Please register to attend. We look forward to meeting you.
Regards,
Raymond Oliver, CEO
Bear Creek Capital
Bringing companies to you up close and personal. Access upper management thru our events while networking with other investors.
If you are looking to gain access to top notch companies working diligently and strategically for their shareholders, these meetings are a great opportunity to access the management team without going thru hurdles such as gate keepers.
Three months to find a scientist to analyze the data? Don't eat that one Elmer, something doesn't smell right! This is almost how he strung us along about nicotine with the tobacco companies, excuses and claiming that he didn't know what the delays were and intimating that their studies were ongoing, when he must of known that they had already walked and at the same time telling us he was in negotiations with even more tobacco companies.
From Mr. Ted Ohashi.
I spoke to CEO Chris Bunka this week and asked him about SRAX, ChargD+, hypertension, etc. I will publish the interview in my free Let's Toke Business newsletter tomorrow. To get a copy send an email to ltbletter@gmail today.
Doesn't make any sense, how it can in as little as four minutes after dosing, deliver 74% more sildenafil into the bloodstream and Seven minutes after dosing, achieved an average blood level higher than the generic sildenafil control formulation reached at any point during the study, but the results are not statistically significant.
Doesn't seem superior at all.
"Of note, the reported improvements in delivery rate including the Cmax, Tmax and AUC evidenced in the study did not achieve statistical significance, therefore, supporting further investigation in a larger number of animals."
Ted Ohashi still bullish on Lexaria. Pg. 15
https://4495825a-d729-4d8f-ade8-e78f828e1c8d.usrfiles.com/ugd/449582_bc6d1a0b6446483797e254f3c5ebb0c3.pdf
One of the reasons I am so enthusiastic about the prospects for Lexaria Bioscience (NASDAQ:
LEXX) (NASDAQ: LEXXW) is they are conducting a wide range of tests of its DehydraTECH™ technology. In the six years or so that I have been following LEXX, DehydraTECH™ has proven to be a very
robust technology and has consistently returned positive results. In the past year, with LEXX listed on the
NASDAQ, we have seen the market respond with some vigor to positive results from testing. However,
as the market assessed the incremental increase in market cap with each result, it was not able to accumulate that value over time. As a result, since the NASDAQ listing, the shares have been up until the
stock price dropped during tax loss selling at year end.
Looking ahead, I think as each prospective application is supported by more data, the market will place a
cumulative valuation on the shares. In addition, we shouldn’t ignore the possibility of a significant breakthrough result that might come at any time.
Here is a summary of the tests completed in 2021 and scheduled for 2022.
16
2021/2022 Study Program
? HYPER-A21-1 - Rodent study completed (n=10) demonstrating significant enhancement in CBD delivery using DehydraTECH - Up to 2,178% more CBD delivered into bloodstream and up to 1,737%
more CBD delivered into brain tissue.
? HYPER-A21-2 - Rodent study completed (n=10) demonstrating strongest CBD absorption results
ever recorded using DehydraTECH - New formulation delivers up to 2,708% more CBD into bloodstream
? HYPER-H21-1 – Human clinical study (n=24) evidencing a rapid and sustained drop in blood pressure
with DehydraTECH-CBD and excellent tolerability
? HYPER-H21-2 - Human clinical study (n=16) Hypoxic Pulmonary Vasoconstriction study; evidences
up to a remarkable 23% decrease in blood pressure with patented DehydraTECH-CBD relative to
placebo and confirms DehydraTECH-CBD reduces arterial stiffness
? VIRAL-C21-3 - In vitro screening assay completed using a primate cell line, VERO-E6, determined
remdesivir and ebastine processed with DehydraTECH were effective at inhibiting the COVID-19
SARS-CoV-2 virus
? VIRAL-A20-2 - Rodent study completed (n=40) DehydraTECH enables up to three-fold increase in
oral delivery of antiviral drugs, Remdesivir and Ebastine
? VIRAL-MC21-1 - Successfully confirmed Lexaria's molecular characterization study objectives,
demonstrating DehydraTECH processing and formulation technology does not create a covalently
bonded new molecular entity (NME) and that each drug tested remained stable and did not undergo
change in chemical structure. These findings are strongly supportive of accelerated regulatory filings
such as the 505(b)(2) pathway permitted by the Food and Drug Administration (FDA) and other international regulators
? VIRAL-A20-3 - Rodent PK study completed (n=20) demonstrating significant enhancement in antiviral drug delivery using DehydraTECH-enabled Colchicine. Possible benefits for treating SARS-CoV2/COVID-19 and mRNA vaccine side effects
? NIC-A21-1 - DehydraTECH-oral nicotine delivery peaked in bloodstream 10x to 20x faster than controls and peak levels achieved were up to 10x higher than controls
The following studies are part of approximately 12 applied R&D programs planned for 2022 (tentative start
dates are included):
? HOR-A22-1: April 2022. This PK study will evaluate the ability of DehydraTECH to enhance the delivery characteristics of estrogen. Estrogen helps to control the menstrual cycle but also controls cholesterol and protects bone health. The hormone replacement market is estimated at $46.5 billion in
2027.
? DEM-A22-1: July 2022. This efficacy study will evaluate DehydraTECH-CBD with and without nicotine
for the potential treatment of dementia. Alzheimer's disease is the most common form of dementia
and accounts for at least 60% of all cases, and nicotine is already showing promising results related
to Alzheimer's treatment. An estimated 55 million people worldwide are currently affected by dementia, with 78 million expected to be living with some form of dementia by 2030. The dementia drug
treatment market is estimated at $19.6 billion in 2026.
17
? RHEUM-A22-1: October 2022. This efficacy study will focus on the ability of DehydraTECH-CBD to
potentially affect treatment of rheumatoid disease. Given CBD's postulated efficacy related to inflammation, Lexaria will explore a possible role for CBD in this area of investigation. Rheumatic diseases
are autoimmune and inflammatory diseases that cause the immune system to attack joints, bones,
muscles and organs. There are over 100 rheumatic diseases including Fibromyalgia, Lupus, Osteoarthritis, Rheumatoid Arthritis and more. The Rheumatoid Arthritis therapeutics market alone is expected to be over $30 billion per year by 2025.
? DIAB-A22-1: November, 2022. This efficacy study will explore the ability of DehydraTECH-CBD to
potentially affect treatment of diabetes. Diabetes prevents the body from making enough insulin, r
esulting in abnormal blood sugar levels. Diabetes is the 7
th largest cause of death in the US and there
is currently no cure. Investigation of CBD related to diabetes is in early stages, though there are
some areas of ongoing investigation. CBD has shown some ability to reduce the incidence of diabetes
in mice. The prescription drug market used to treat diabetes is expected to be a $77.9 billion global
market in 2024.
Conclusion: with a patented technology that improves the way active pharmaceutical ingredients enter
the bloodstream and its listing on the NASDAQ early this year, Lexaria Bioscience (NASDAQ: LEXX,
LEXXW) has successfully disassociated itself from
the cannabis industry. Thus,
while the cannabis
group is down
sharply since February 2021, LEXX has been able to maintain its value in that time frame. Of course, cannabinoids remain
important to LEXX but now as an active pharmaceutical ingredient. To give you a sense of the breadth of
areas being investigated, consider the following list: dementia (Alzheimer’s), diabetes, heart disease, hormone replacement, hypertension, Lupus, oral nicotine, Osteoarthritis, and rheumatoid diseases (Fibromyalgia, Rheumatoid Arthritis). The work is fully funded through all of 2022 and the first half of 2023. As a
result, I believe LEXX and LEXXW holders will have several event related positive moves in the market
in 2022. I suggest every growth portfolio should earn LEXX and/or LEXXW
It appears that Cannadips CBD pouches are a complete bust. Production has stopped and they are stuck with unsold inventory. People are not interested in getting their CBD by sucking on a pouch it seems. I think that Cannadips will have more success with their THC pouches, but of course we won't get any revenue from that product.
Revenue
Product revenues of $7k and licensing usage fees of $Nil during period ended November 30, 2021, constitute a significant decline in intermediate product sales and related licensing
usage fees. Our primary customer in the B2B product revenue stream has been delayed in chainstore rollouts due resulting in overstocked inventory and as such there was no
manufacturing & sales of new inventory for this licensee for the quarter ended November 30, 2021.A number of our other licensees are experiencing suspended or curtailed business
activities due to the impact of COVID19 on markets and consumer spending. The abilities of other licensees to generate ongoing sales, thereby increasing usage fees are expected to
increase as the effects of the pandemic are eventually diminished. We have continued strong interest in our intermediate products but cannot predict how long the pandemic will affect
purchasing decisions of retail customers that ultimately affect the consumer product manufacturers that utilize our intermediate products. Nor can we predict when recovery of the
general economy will translate into increasing licensing or usage revenues.
Quarterly Report is out and it's a disaster, revenue has cratered to only $13,880.00 and net loss has soared to $2,000,000. No wonder they waited till long after the bell on a Friday to release this.
http://www.stockwatch.com/News/Sedardoc/5016611.pdf
Complaining is unlikely to draw a response from IR.
insert-text-here
Introducing Elev8 - Dehydr8 Michigan’s brand powered by Hill Avenue’s fast-acting DehydraTECH™? technology.
Lexaria’s Clinical Hypertension Study HYPER-H21-3 Nears Completion
https://mailchi.mp/lexariabioscience.com/lexarias-dehydratech-enabled-remdesivir-and-ebastine-effectively-inhibit-the-covid-19-sars-cov-2-virus-2692389?e=aa4bd7bcad
Here's Lexaria's presentation on Benzinga for those that missed it. 27 min.
Benzinga
HYPER-H21-3
DehydraTECH-CBD manufacturing for this study is complete and the clinical test articles have been delivered to the study location where dosing is expected to begin in mid-November or thereabouts, and dosing is expected to be complete by mid-December. Thereafter, the BP findings are expected to be reportable by the end of January, 2022.
HYPER-H21-3 will be conducted in 16 adult volunteers and will utilize a single dose of 300mg of DehydraTECH-CBD. This study is designed to evaluate acute pulmonary hypertension and cardiovascular effects under severe stress. Exposure to acute reductions in oxygen tension (i.e., hypoxia) causes rapid hypoxic pulmonary vasoconstriction ("HPV") and, as a consequence of this HPV response, pulmonary arterial pressure increases. If this increase in pressure becomes too high, as is the case in many cardiac pathologies, an excess of fluid in the lungs can occur that causes difficulty with breathing. The extent to which DehydraTECH-CBD may act as a novel treatment for HPV, and potentially as an alternative treatment for pulmonary hypertension, is unknown. Thus, the primary objective of this study is to evaluate the effect of DehydraTECH-CBD on pulmonary vascular function in normotensive individuals exposed to hypoxia. The magnitude of HPV, blood pressure, heart rate, blood samples, and pulmonary gas exchange data will be collected and analyzed.
Thanks Abundance!